Cravath, Vinson & Elkins Steer Biogen's $7.3B Reata Buy
Biotechnology company Biogen Inc. will buy biopharmaceutical company Reata Pharmaceuticals Inc. in a cash deal with an enterprise value of roughly $7.3 billion, according to a Friday announcement....To view the full article, register now.
Already a subscriber? Click here to view full article